United Therapeutics Corp
NASDAQ:UTHR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
United Therapeutics Corp
NASDAQ:UTHR
|
US |
|
V
|
Valneva SE
XMUN:AYJ
|
FR |
|
Libas Consumer Products Ltd
NSE:LIBAS
|
IN |
|
V
|
Ventas Inc
SWB:VEN
|
US |
|
A
|
AES Corp
SWB:AES
|
US |
|
A
|
Axon Enterprise Inc
F:TCS
|
US |
Intrinsic Value
Is UTHR undervalued or overvalued?
See the intrinsic value estimate for United Therapeutics Corp and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What United Therapeutics Does
United Therapeutics is a biotechnology company focused on serious, long-term diseases where patients often need ongoing treatment. Its main business is making medicines for pulmonary hypertension, a condition that raises blood pressure in the lungs and can become life threatening. The company also works on organ manufacturing and transplant-related technologies, which reflects its goal of finding treatments for patients with very limited options.
- Headquarters
- United States of America US
- Employees
- 1 400
- IPO date
- Jun 17, 1999
United Therapeutics has a narrow economic moat
Patents covering key medicines and their delivery technology prevent rivals from freely copying parts of United Therapeutics’ treatments. For some Remodulin patients, changing treatment also means learning a different pump system and carefully managing an uninterrupted drug supply, making a cheaper rival less straightforward to adopt.
Read the full moat analysis
Revenue & Expenses Breakdown
United Therapeutics Corp
Earnings Waterfall
United Therapeutics Corp
The intrinsic value for United Therapeutics Corp (UTHR) under the Base Case is hidden USD.
Compared with the current market price of 601.505 USD, the stock appears hidden.